Mountain View, CA (February 10, 2017) – Fenwick & West has been named among the Life Sciences Law Firm Index Top Deal Firms by Lake Whillans. Fenwick ranked fourth on the list based on the firm’s transactional achievements over the course of 2016.
Lake Whillans highlighted Fenwick’s representation of Cepheid in its $4 billion acquisition by Danaher as one of 2016’s key life sciences transactions. In 2016, Fenwick also represented Aeglea BioTherapeutics, Audentes Therapeutics and Obalon Therapeutics in their IPOs, as well as handling financings and follow-on offerings for a number of life sciences companies.
The Life Sciences Law Firm Index identifies the most active and relevant law firms for life sciences companies, using criteria most important to healthcare innovators. The Top Deal Firms ranking considers all aspects of the corporate and transactional practice, including mergers and acquisitions, IPOs, financing and private equity work. Lake Whillans also looks at the most significant IPO and M&A activity in the life sciences space over the course of 2016.
For 40 years, Fenwick’s life sciences group, comprised of lawyers, patent agents and scientific advisors, have served emerging and established companies in the life sciences, mHealth, digital heath and healthcare IT industries, as well as leading research institutions.
About Fenwick & West
Fenwick & West LLP provides comprehensive legal services to ground-breaking technology and life sciences companies – at every stage of their lifecycle – and the investors that partner with them. We craft innovative, cost-effective and practical solutions on issues ranging from venture capital, public offerings, joint ventures, M&A and strategic relationships, to intellectual property, litigation and dispute resolution, taxation, antitrust, and employment and labor law. For more than four decades, Fenwick has helped some of the world's most recognized companies become and remain market leaders. For more information, please visit fenwick.com.